Jouet J P
Hôpital Claude-Huriez Service des maladies du sang, Lille.
Rev Prat. 1997 Nov 15;47(18 Spec No):S47-49.
When allogeneic stem cells transplantations are still considered as high risk therapies concerning few people, at present autologous stem cells transplantations take place in many therapeutic protocols of many malignant diseases even if clinical evaluation is not always really performed. Challenges in a close future consist in the decrease of the incidence of complications (of the immunological type essentially) of allogenic transplants without reducing the "graft versus leukemia effect", and the decrease of the risk of relapses after autologous transplantations.
当同种异体干细胞移植对于少数人而言仍被视为高风险治疗方法时,目前自体干细胞移植在许多恶性疾病的众多治疗方案中都有应用,即便并非总是真正进行临床评估。在不久的将来,面临的挑战包括降低同种异体移植并发症(主要是免疫类型的并发症)的发生率,同时又不降低“移植物抗白血病效应”,以及降低自体移植后复发的风险。